Suracell Selects BioServe as Exclusive DNA Testing Partner
News Jun 28, 2007
Suracell has developed a proprietary and fully integrated information technology platform to identify genetic markers related to a number of biological processes that have been shown to be associated with healthy aging.
Suracell's proprietary DNA assessment is a key component of an innovative personal genetic health program that provides the basis for developing personalized recommendations. Suracell's programs are formulated to address each person's unique genetic inheritance as it relates to healthy aging.
Suracell has also developed a proprietary "genetic testing web portal" that provides an integrated solution to the collection and processing of samples from a single source or multiple sources and dissemination of the results of both DNA testing and other specialized laboratory tests.
Through this agreement, BioServe will receive samples collected from patients seeking to take advantage of Suracell's programs. BioServe extracts DNA from a buccal swab collected from the de-identified patient. Next, the DNA quality is verified before undergoing analysis using a panel of proprietary single nucleotide polymorphisms (SNPs) selected by Suracell. BioServe then transmits the analyzed data back to Suracell using Suracell's proprietary information technology platform.
Suracell subsequently delivers the results to the requesting physicians and health care practitioners. BioServe is one of the few DNA testing laboratories that have been awarded the CLIA certification.
BioServe claims that it is the first company to provide DNA testing services to utilize Suracell's genetic testing web portal. This portal provides a single point of access for physicians and health care centers, allowing them to use the internet to order genetic testing services for patients from participating laboratory service providers, as well as allowing for secure online delivery of test results in a format of their choosing. It also provides composite results based on input from multiple tests and other relevant data.
Bernie Landes, Suracell Chairman and Chief Executive Officer, said, "Suracell's "Personal Genetic Health" program and its proprietary Information Technology platform are exciting breakthroughs in both the field of personal genetic health and genetic testing. Through this partnership we will leverage BioServe's comprehensive genetic and molecular testing services and expertise to help Suracell clients better understand how their genetic inheritance relates to their health and well being throughout the aging process. In addition, BioServe's commitment to taking a leadership role in genetic testing makes them a perfect partner for Suracell's proprietary Information Technology platform."
Kevin Krenitsky M.D., Chief Executive Officer, BioServe, said, "This is an exciting time in the science of genetics as it relates to healthy aging and personalized medicine. Understanding the relationship between genetics and healthy aging is critical as our population ages and we hope to not only help Suracell expand its personal genetic business, but also use the company's unique technology platform to spearhead BioServe's growth to a global position of leadership in the field of genetic testing. We are excited to work with Suracell on both of these exciting initiatives."
Terms of the deal were not disclosed and discussions are ongoing to develop a more comprehensive partnership between the two companies.
There are hundreds of thousands of structural variants (SVs) in the human genome that are hard to identify than single nucleotide variants. Researchers have used a full suite of genomic technologies to analyze the number of SVs in three individuals, and the results present as the most comprehensive catalog of SVS to date.READ MORE